ECSP19091293A - Nuevas formulaciones orales de belinostat - Google Patents

Nuevas formulaciones orales de belinostat

Info

Publication number
ECSP19091293A
ECSP19091293A ECSENADI201991293A ECDI201991293A ECSP19091293A EC SP19091293 A ECSP19091293 A EC SP19091293A EC SENADI201991293 A ECSENADI201991293 A EC SENADI201991293A EC DI201991293 A ECDI201991293 A EC DI201991293A EC SP19091293 A ECSP19091293 A EC SP19091293A
Authority
EC
Ecuador
Prior art keywords
belinostat
oral formulations
new oral
new
formulations
Prior art date
Application number
ECSENADI201991293A
Other languages
English (en)
Inventor
Ian Yates
Perrine Pivette
Corey Bloom
Caroline Lemarchand
Original Assignee
Onxeo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo filed Critical Onxeo
Publication of ECSP19091293A publication Critical patent/ECSP19091293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

La presente solicitud se refiere a nuevas formulaciones de belinostat adecuadas para administración oral, su proceso de preparación, las composiciones farmacéuticas que comprenden dichas formulaciones y sus usos.
ECSENADI201991293A 2017-06-30 2019-12-26 Nuevas formulaciones orales de belinostat ECSP19091293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527684P 2017-06-30 2017-06-30
EP17305853 2017-07-03

Publications (1)

Publication Number Publication Date
ECSP19091293A true ECSP19091293A (es) 2020-05-29

Family

ID=62816549

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201991293A ECSP19091293A (es) 2017-06-30 2019-12-26 Nuevas formulaciones orales de belinostat

Country Status (24)

Country Link
US (1) US11266614B2 (es)
EP (1) EP3644970B8 (es)
JP (1) JP7247122B2 (es)
CN (1) CN110996913A (es)
AU (1) AU2018294561B2 (es)
BR (1) BR112019028088A8 (es)
CA (1) CA3067723A1 (es)
CL (1) CL2019003801A1 (es)
CO (1) CO2019014831A2 (es)
CY (1) CY1125762T1 (es)
DK (1) DK3644970T3 (es)
EC (1) ECSP19091293A (es)
ES (1) ES2909583T3 (es)
HR (1) HRP20220309T1 (es)
HU (1) HUE057999T2 (es)
IL (1) IL271658B2 (es)
LT (1) LT3644970T (es)
MX (1) MX393915B (es)
PE (1) PE20241993A1 (es)
PL (1) PL3644970T3 (es)
RS (1) RS63046B1 (es)
SI (1) SI3644970T1 (es)
SM (1) SMT202200191T1 (es)
ZA (1) ZA201908532B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2021188695A1 (en) * 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063831A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
AU2012213940B2 (en) 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
JP2007045788A (ja) 2005-08-12 2007-02-22 Kenjiro Koga グリチルリチン酸高濃度水溶液の調製法
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2011064663A1 (en) * 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
EP2572731A1 (en) 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
US9114170B2 (en) * 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
US20170095484A1 (en) 2014-05-02 2017-04-06 Oncoethix Gmbh Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma
JP2017095428A (ja) 2015-11-27 2017-06-01 国立大学法人神戸大学 脂質代謝改善剤
WO2018029699A1 (en) * 2016-08-11 2018-02-15 Msn Research & Development Center Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof

Also Published As

Publication number Publication date
AU2018294561B2 (en) 2023-12-07
CN110996913A (zh) 2020-04-10
CA3067723A1 (en) 2019-01-03
CO2019014831A2 (es) 2020-04-24
IL271658A (en) 2020-02-27
DK3644970T3 (da) 2022-03-14
HUE057999T2 (hu) 2022-06-28
HRP20220309T1 (hr) 2022-05-13
JP7247122B2 (ja) 2023-03-28
EP3644970B1 (en) 2022-02-09
AU2018294561A1 (en) 2020-01-16
PE20241993A1 (es) 2024-09-27
CY1125762T1 (el) 2024-02-16
US11266614B2 (en) 2022-03-08
BR112019028088A8 (pt) 2022-11-08
BR112019028088A2 (pt) 2020-07-28
IL271658B2 (en) 2023-09-01
SI3644970T1 (sl) 2022-05-31
MX2019015869A (es) 2020-08-06
IL271658B1 (en) 2023-05-01
SMT202200191T1 (it) 2022-07-21
LT3644970T (lt) 2022-04-25
EP3644970B8 (en) 2022-03-16
ES2909583T3 (es) 2022-05-09
JP2020525499A (ja) 2020-08-27
EP3644970A1 (en) 2020-05-06
US20200155485A1 (en) 2020-05-21
PL3644970T3 (pl) 2022-04-25
MX393915B (es) 2025-03-24
ZA201908532B (en) 2022-07-27
RS63046B1 (sr) 2022-04-29
CL2019003801A1 (es) 2020-09-11

Similar Documents

Publication Publication Date Title
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
ECSP18014922A (es) Composiciones de insulina de rápida acción
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX386820B (es) Microcápsulas lipídicas que comprenden de preferencia un retinoide y composición que las contiene, su procedimiento de preparación y su uso en dermatología.
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
ECSP13012368A (es) Composiciones farmacéuticas de co-cristales de tramadol y coxibs
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CU20210077A7 (es) Extractos bacterianos estables como fármacos
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CL2018001742A1 (es) Compuestos indolinones y sus usos en el tratamiento de enfermedades fibroticas.
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat
MX2020004675A (es) Formulaciones de alcohol de seda.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX385867B (es) Composicion lipida vegetal para promover el crecimiento del cabello, metodo para promover el crecimiento del cabello y uso de los lipidos vegetales.
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
CO2019000083A2 (es) Composiciones farmacéuticas
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
UY38217A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona
MX2018003202A (es) Formas cristalinas.